New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies

David W. Scott, Pau Abrisqueta, George W. Wright, Graham W. Slack, Anja Mottok, Diego Villa, Pedro Jares, Hilka Rauert-Wunderlich, Cristina Royo, Guillem Clot, Magda Pinyol, Merrill Boyle, Fong Chun Chan, Rita M. Braziel, Wing C. Chan, Dennis D. Weisenburger, James R. Cook, Timothy C. Greiner, Kai Fu, German OttJan Delabie, Erlend B. Smeland, Harald Holte, Elaine S. Jaffe, Christian Steidl, Joseph M. Connors, Randy D. Gascoyne, Andreas Rosenwald, Louis M. Staudt, Elias Campo, Lisa M Rimsza

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose Mantle cell lymphoma is an aggressive B-cell neoplasm that displays heterogeneous outcomes after treatment. In 2003, the Lymphoma/Leukemia Molecular Profiling Project described a powerful biomarker—the proliferation signature—using gene expression in fresh frozen material. Herein, we describe the training and validation of a new assay that measures the proliferation signature in RNA derived from routinely available formalin-fixed paraffin-embedded (FFPE) biopsies. Methods Forty-seven FFPE biopsies were used to train an assay on the NanoString platform, using microarray gene expression data of matched fresh frozen biopsies as a gold standard. The locked assay was applied to pretreatment FFPE lymph node biopsies from an independent cohort of 110 patients uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Seventeen biopsies were tested across three laboratories to assess assay reproducibility. Results The MCL35 assay, which contained a 17-gene proliferation signature, yielded gene expression of sufficient quality to assign an assay score and risk group in 108 (98%) of 110 archival FFPE biopsies. The MCL35 assay assigned patients to high-risk (26%), standard-risk (29%), and low-risk (45%) groups, with different lengths of overall survival (OS): a median of 1.1, 2.6, and 8.6 years, respectively (log-rank for trend, P, .001). In multivariable analysis, these risk groups and the Mantle Cell Lymphoma International Prognostic Index were independently associated with OS (P, .001 for both variables). Concordance of risk assignment across the three independent laboratories was 100%. Conclusion The newly developed and validated MCL35 assay for FFPE biopsies uses the proliferation signature to define groups of patients with significantly different OS independent of the Mantle Cell Lymphoma International Prognostic Index. Importantly, the analytic and clinical validity of this assay defines it as a reliable biomarker to support risk-adapted clinical trials.

Original languageEnglish (US)
Pages (from-to)1668-1677
Number of pages10
JournalJournal of Clinical Oncology
Volume35
Issue number15
DOIs
StatePublished - May 20 2017
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Paraffin
Formaldehyde
Biopsy
Survival
Gene Expression
Vincristine
Prednisone
Transcriptome
Doxorubicin
Cyclophosphamide
Lymphoma
Leukemia
B-Lymphocytes
Biomarkers
Lymph Nodes
Clinical Trials
RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. / Scott, David W.; Abrisqueta, Pau; Wright, George W.; Slack, Graham W.; Mottok, Anja; Villa, Diego; Jares, Pedro; Rauert-Wunderlich, Hilka; Royo, Cristina; Clot, Guillem; Pinyol, Magda; Boyle, Merrill; Chan, Fong Chun; Braziel, Rita M.; Chan, Wing C.; Weisenburger, Dennis D.; Cook, James R.; Greiner, Timothy C.; Fu, Kai; Ott, German; Delabie, Jan; Smeland, Erlend B.; Holte, Harald; Jaffe, Elaine S.; Steidl, Christian; Connors, Joseph M.; Gascoyne, Randy D.; Rosenwald, Andreas; Staudt, Louis M.; Campo, Elias; Rimsza, Lisa M.

In: Journal of Clinical Oncology, Vol. 35, No. 15, 20.05.2017, p. 1668-1677.

Research output: Contribution to journalArticle

Scott, DW, Abrisqueta, P, Wright, GW, Slack, GW, Mottok, A, Villa, D, Jares, P, Rauert-Wunderlich, H, Royo, C, Clot, G, Pinyol, M, Boyle, M, Chan, FC, Braziel, RM, Chan, WC, Weisenburger, DD, Cook, JR, Greiner, TC, Fu, K, Ott, G, Delabie, J, Smeland, EB, Holte, H, Jaffe, ES, Steidl, C, Connors, JM, Gascoyne, RD, Rosenwald, A, Staudt, LM, Campo, E & Rimsza, LM 2017, 'New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies', Journal of Clinical Oncology, vol. 35, no. 15, pp. 1668-1677. https://doi.org/10.1200/JCO.2016.70.7901
Scott, David W. ; Abrisqueta, Pau ; Wright, George W. ; Slack, Graham W. ; Mottok, Anja ; Villa, Diego ; Jares, Pedro ; Rauert-Wunderlich, Hilka ; Royo, Cristina ; Clot, Guillem ; Pinyol, Magda ; Boyle, Merrill ; Chan, Fong Chun ; Braziel, Rita M. ; Chan, Wing C. ; Weisenburger, Dennis D. ; Cook, James R. ; Greiner, Timothy C. ; Fu, Kai ; Ott, German ; Delabie, Jan ; Smeland, Erlend B. ; Holte, Harald ; Jaffe, Elaine S. ; Steidl, Christian ; Connors, Joseph M. ; Gascoyne, Randy D. ; Rosenwald, Andreas ; Staudt, Louis M. ; Campo, Elias ; Rimsza, Lisa M. / New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. In: Journal of Clinical Oncology. 2017 ; Vol. 35, No. 15. pp. 1668-1677.
@article{0614435659924b208fbf89247001dc55,
title = "New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies",
abstract = "Purpose Mantle cell lymphoma is an aggressive B-cell neoplasm that displays heterogeneous outcomes after treatment. In 2003, the Lymphoma/Leukemia Molecular Profiling Project described a powerful biomarker—the proliferation signature—using gene expression in fresh frozen material. Herein, we describe the training and validation of a new assay that measures the proliferation signature in RNA derived from routinely available formalin-fixed paraffin-embedded (FFPE) biopsies. Methods Forty-seven FFPE biopsies were used to train an assay on the NanoString platform, using microarray gene expression data of matched fresh frozen biopsies as a gold standard. The locked assay was applied to pretreatment FFPE lymph node biopsies from an independent cohort of 110 patients uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Seventeen biopsies were tested across three laboratories to assess assay reproducibility. Results The MCL35 assay, which contained a 17-gene proliferation signature, yielded gene expression of sufficient quality to assign an assay score and risk group in 108 (98{\%}) of 110 archival FFPE biopsies. The MCL35 assay assigned patients to high-risk (26{\%}), standard-risk (29{\%}), and low-risk (45{\%}) groups, with different lengths of overall survival (OS): a median of 1.1, 2.6, and 8.6 years, respectively (log-rank for trend, P, .001). In multivariable analysis, these risk groups and the Mantle Cell Lymphoma International Prognostic Index were independently associated with OS (P, .001 for both variables). Concordance of risk assignment across the three independent laboratories was 100{\%}. Conclusion The newly developed and validated MCL35 assay for FFPE biopsies uses the proliferation signature to define groups of patients with significantly different OS independent of the Mantle Cell Lymphoma International Prognostic Index. Importantly, the analytic and clinical validity of this assay defines it as a reliable biomarker to support risk-adapted clinical trials.",
author = "Scott, {David W.} and Pau Abrisqueta and Wright, {George W.} and Slack, {Graham W.} and Anja Mottok and Diego Villa and Pedro Jares and Hilka Rauert-Wunderlich and Cristina Royo and Guillem Clot and Magda Pinyol and Merrill Boyle and Chan, {Fong Chun} and Braziel, {Rita M.} and Chan, {Wing C.} and Weisenburger, {Dennis D.} and Cook, {James R.} and Greiner, {Timothy C.} and Kai Fu and German Ott and Jan Delabie and Smeland, {Erlend B.} and Harald Holte and Jaffe, {Elaine S.} and Christian Steidl and Connors, {Joseph M.} and Gascoyne, {Randy D.} and Andreas Rosenwald and Staudt, {Louis M.} and Elias Campo and Rimsza, {Lisa M}",
year = "2017",
month = "5",
day = "20",
doi = "10.1200/JCO.2016.70.7901",
language = "English (US)",
volume = "35",
pages = "1668--1677",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "15",

}

TY - JOUR

T1 - New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies

AU - Scott, David W.

AU - Abrisqueta, Pau

AU - Wright, George W.

AU - Slack, Graham W.

AU - Mottok, Anja

AU - Villa, Diego

AU - Jares, Pedro

AU - Rauert-Wunderlich, Hilka

AU - Royo, Cristina

AU - Clot, Guillem

AU - Pinyol, Magda

AU - Boyle, Merrill

AU - Chan, Fong Chun

AU - Braziel, Rita M.

AU - Chan, Wing C.

AU - Weisenburger, Dennis D.

AU - Cook, James R.

AU - Greiner, Timothy C.

AU - Fu, Kai

AU - Ott, German

AU - Delabie, Jan

AU - Smeland, Erlend B.

AU - Holte, Harald

AU - Jaffe, Elaine S.

AU - Steidl, Christian

AU - Connors, Joseph M.

AU - Gascoyne, Randy D.

AU - Rosenwald, Andreas

AU - Staudt, Louis M.

AU - Campo, Elias

AU - Rimsza, Lisa M

PY - 2017/5/20

Y1 - 2017/5/20

N2 - Purpose Mantle cell lymphoma is an aggressive B-cell neoplasm that displays heterogeneous outcomes after treatment. In 2003, the Lymphoma/Leukemia Molecular Profiling Project described a powerful biomarker—the proliferation signature—using gene expression in fresh frozen material. Herein, we describe the training and validation of a new assay that measures the proliferation signature in RNA derived from routinely available formalin-fixed paraffin-embedded (FFPE) biopsies. Methods Forty-seven FFPE biopsies were used to train an assay on the NanoString platform, using microarray gene expression data of matched fresh frozen biopsies as a gold standard. The locked assay was applied to pretreatment FFPE lymph node biopsies from an independent cohort of 110 patients uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Seventeen biopsies were tested across three laboratories to assess assay reproducibility. Results The MCL35 assay, which contained a 17-gene proliferation signature, yielded gene expression of sufficient quality to assign an assay score and risk group in 108 (98%) of 110 archival FFPE biopsies. The MCL35 assay assigned patients to high-risk (26%), standard-risk (29%), and low-risk (45%) groups, with different lengths of overall survival (OS): a median of 1.1, 2.6, and 8.6 years, respectively (log-rank for trend, P, .001). In multivariable analysis, these risk groups and the Mantle Cell Lymphoma International Prognostic Index were independently associated with OS (P, .001 for both variables). Concordance of risk assignment across the three independent laboratories was 100%. Conclusion The newly developed and validated MCL35 assay for FFPE biopsies uses the proliferation signature to define groups of patients with significantly different OS independent of the Mantle Cell Lymphoma International Prognostic Index. Importantly, the analytic and clinical validity of this assay defines it as a reliable biomarker to support risk-adapted clinical trials.

AB - Purpose Mantle cell lymphoma is an aggressive B-cell neoplasm that displays heterogeneous outcomes after treatment. In 2003, the Lymphoma/Leukemia Molecular Profiling Project described a powerful biomarker—the proliferation signature—using gene expression in fresh frozen material. Herein, we describe the training and validation of a new assay that measures the proliferation signature in RNA derived from routinely available formalin-fixed paraffin-embedded (FFPE) biopsies. Methods Forty-seven FFPE biopsies were used to train an assay on the NanoString platform, using microarray gene expression data of matched fresh frozen biopsies as a gold standard. The locked assay was applied to pretreatment FFPE lymph node biopsies from an independent cohort of 110 patients uniformly treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Seventeen biopsies were tested across three laboratories to assess assay reproducibility. Results The MCL35 assay, which contained a 17-gene proliferation signature, yielded gene expression of sufficient quality to assign an assay score and risk group in 108 (98%) of 110 archival FFPE biopsies. The MCL35 assay assigned patients to high-risk (26%), standard-risk (29%), and low-risk (45%) groups, with different lengths of overall survival (OS): a median of 1.1, 2.6, and 8.6 years, respectively (log-rank for trend, P, .001). In multivariable analysis, these risk groups and the Mantle Cell Lymphoma International Prognostic Index were independently associated with OS (P, .001 for both variables). Concordance of risk assignment across the three independent laboratories was 100%. Conclusion The newly developed and validated MCL35 assay for FFPE biopsies uses the proliferation signature to define groups of patients with significantly different OS independent of the Mantle Cell Lymphoma International Prognostic Index. Importantly, the analytic and clinical validity of this assay defines it as a reliable biomarker to support risk-adapted clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85022210295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022210295&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.70.7901

DO - 10.1200/JCO.2016.70.7901

M3 - Article

C2 - 28291392

AN - SCOPUS:85022210295

VL - 35

SP - 1668

EP - 1677

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

ER -